Meridian Bioscience Inc Revenue Growth Rates (VIVO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Meridian Bioscience Inc   (NASDAQ: VIVO)
 

VIVO's Revenue Growth by Quarter and Year

Meridian Bioscience Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VIVO Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter September -
3rd Quarter June -
2nd Quarter March -
1st Quarter December 56.90
FY 56.90

VIVOs Annual Revenue
Meridian Bioscience Inc 's Revenue in the fiscal year 2022 $ 333.02 millions
Meridian Bioscience Inc 's Revenue in the fiscal year 2021 $ 317.90 millions
Meridian Bioscience Inc 's Revenue in the fiscal year 2020 $ 253.67 millions
Meridian Bioscience Inc 's Revenue in the fiscal year 2019 $ 201.01 millions
Meridian Bioscience Inc 's Revenue in the fiscal year 2018 $ 213.57 millions




VIVO Revenue first quarter 2022 Y/Y Growth Comment
Meridian Bioscience Inc reported fall in Revenue in the first quarter 2022 by -35.59% to $ 56.90 millions, from the same quarter in 2021.
This represents worst decline in recent Company history.

Looking into first quarter 2022 results within In Vitro & In Vivo Diagnostic Substances industry 15 other companies have achieved higher Revenue growth. While Meridian Bioscience Inc ' s Revenue drop of -35.59% ranks overall at the positon no. 4144 in the first quarter 2022.


VIVO Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter September - -13.81 % 18.78 % 26.16 %
3rd Quarter June - 6.71 % -25.11 % 75.06 %
2nd Quarter March - 30.46 % 48.8 % 14.03 %
1st Quarter December -35.59 % -4.93 % 95.95 % -7.89 %
FY   - 4.76 % 25.32 % -

Financial Statements
Meridian Bioscience Inc 's first quarter 2022 Revenue $ 56.90 millions VIVO's Income Statement
Meridian Bioscience Inc 's first quarter 2021 Revenue $ 88.34 millions Quarterly VIVO's Income Statement


VIVO Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter September - -3.08 % 19.98 % -24.35 %
3rd Quarter June - -39.07 % -25.51 % 47.99 %
2nd Quarter March - 25.91 % -8.24 % 20.84 %
1st Quarter December -13.36 % 15.93 % 44.85 % -6.75 %
FY (Year on Year)   - 4.76 % 25.32 % -


Back to VIVO Growth rate Comparisons >> Back to VIVO Growth rate Comparisons >>


Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #16
Healthcare Sector #634
Overall #4144

Revenue Y/Y Growth Statistics
High Average Low
95.94 % 7.41 % -35.59 %
(Dec 31 2020)   (Dec 31 2022)
Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #16
Healthcare Sector #634
Overall #4144
Revenue Y/Y Growth Statistics
High Average Low
95.94 % 7.41 % -35.59 %
(Dec 31 2020)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Meridian Bioscience Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
48 % 2.15 % -39.07 %
(Jun 30 2020)  


VIVO's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2022 Meridian Bioscience Inc disclosed drop in Revenue from the fourth quarter by -13.36% to $ 56.90 millions, from $ 65.68 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2022 Revenue, this plainly could not be substantial to rescue In Vitro & In Vivo Diagnostic Substances's company achievement, Most analysts pointed out.

Within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher Revenue quarter on quarter growth. While Meridian Bioscience Inc 's Revenue growth quarter on quarter, overall rank is 3048.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #14
Healthcare Sector #450
Overall #3048
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #14
Healthcare Sector #450
Overall #3048
Revenue Q/Q Growth Statistics
High Average Low
48 % 2.15 % -39.07 %
(Jun 30 2020)  


VIVO's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2022 Meridian Bioscience Inc disclosed drop in Revenue from the fourth quarter by -13.36% to $ 56.90 millions, from $ 65.68 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2022 Revenue, this plainly could not be substantial to rescue In Vitro & In Vivo Diagnostic Substances's company achievement, Most analysts pointed out.

Within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher Revenue quarter on quarter growth. While Meridian Bioscience Inc 's Revenue growth quarter on quarter, overall rank is 3048.


Meridian Bioscience Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 301.58 $ 333.02 $ 343.55 $ 339.29 $ 313.32
Y / Y Revenue Growth (TTM) -3.75 % 4.76 % 12.33 % 3.72 % 4.73 %
Year on Year Revenue Growth Overall Ranking # 2738 # 0 # 1437 # 1509 # 2888
Seqeuential Revenue Change (TTM) -9.44 % -3.06 % 1.26 % 8.29 % -1.44 %
Seq. Revenue Growth (TTM) Overall Ranking # 3052 # 0 # 1895 # 388 # 314


Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2022 Meridian Bioscience Inc reported a decrease in Revenue by -3.75% year on year, to $302 millions, compare to the 4.76% growth at Sep 30 2022.

In the Healthcare sector 377 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2738.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 10
Healthcare Sector # 378
Overall # 2738

Revenue TTM Y/Y Growth Statistics
High Average Low
60.36 %
 7.6 %
-7.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 419
S&P 500 # 3052
Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2022 Meridian Bioscience Inc reported a decrease in Revenue by -3.75% year on year, to $302 millions, compare to the 4.76% growth at Sep 30 2022.

In the Healthcare sector 377 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2738.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 10
Healthcare Sector # 378
Overall # 2738

Revenue TTM Y/Y Growth Statistics
High Average Low
60.36 %
7.6 %
-7.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 419
S&P 500 # 3052




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VIVO's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Amgen Inc -0.10%$ -0.102 millions
Bausch Health Companies Inc -0.14%$ -0.137 millions
Bio rad Laboratories Inc -0.34%$ -0.339 millions
Nrc Health-0.40%$ -0.402 millions
Asensus Surgical Inc -0.48%$ -0.485 millions
Bausch and Lomb Corp-0.50%$ -0.500 millions
Teleflex Incorporated-0.51%$ -0.514 millions
Elite Pharmaceuticals Inc -0.62%$ -0.619 millions
Meihua International Medical Technologies Co Ltd-0.66%$ -0.665 millions
Ambrx Biopharma Inc -0.71%$ -0.711 millions
Chemed Corporation-0.85%$ -0.851 millions
Vycor Medical Inc -0.90%$ -0.899 millions
Fonar Corporation-0.91%$ -0.911 millions
Davita Inc -0.92%$ -0.920 millions
Syneos Health Inc -0.98%$ -0.984 millions
Reshape Lifesciences Inc-1.02%$ -1.018 millions
Accuray Incorporated-1.30%$ -1.303 millions
Bellicum Pharmaceuticals Inc -1.57%$ -1.575 millions
Pliant Therapeutics Inc -1.70%$ -1.701 millions
Royalty Pharma Plc-1.73%$ -1.729 millions
Precipio inc -1.81%$ -1.807 millions
Integra Lifesciences Holdings Corp-1.85%$ -1.850 millions
Nexgel Inc -1.88%$ -1.876 millions
Novartis Ag-1.98%$ -1.984 millions
Theravance Biopharma inc -1.99%$ -1.987 millions
Orthofix Medical Inc -2.27%$ -2.267 millions
Travere Therapeutics Inc -2.41%$ -2.412 millions
Heska Corporation-2.54%$ -2.542 millions
Sangamo Therapeutics Inc -2.70%$ -2.701 millions
Glaukos Corp-2.75%$ -2.748 millions


About Meridian Bioscience Inc Revenue Growth Rates (VIVO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Meridian Bioscience Inc (CIK 794172).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-23-029272
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Meridian Bioscience Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.